Calciphylaxis: Treatment and outlook—CME part II

Jonathan Rick; Renajd Rrapi; Sidharth Chand; Michi M. Shinohara; Lindsay Strowd; Helena B. Pasieka; Robert Micheletti; Daniela Kroshinsky; Alex G. Ortega-Loayza

doi:10.1016/j.jaad.2021.10.063

Calciphylaxis: Treatment and outlook—CME part II

Jonathan Rick, Renajd Rrapi, Sidharth Chand, Michi M. Shinohara, Lindsay Strowd, Helena B. Pasieka, Robert Micheletti, Daniela Kroshinsky, Alex G. Ortega-Loayza^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Calciphylaxis is a rare and devastating condition with important systemic ramifications. This second-part of our CME aims to educate the practicing dermatologist on the current standard of care once a diagnosis of calciphylaxis is confirmed or highly suspected. The key pathologic findings, as well as the role and limitations of biopsy, are reviewed. We aim to guide readers through the complex hospitalization and posthospitalization management of these medically vulnerable patients. Collaboration with other specialists will be discussed. Experimental and developing treatments are discussed, and the outlook of the condition is reported.

Original language	English
Pages (from-to)	985-992
Number of pages	8
Journal	Journal of the American Academy of Dermatology
Volume	86
Issue number	5
DOIs	https://doi.org/10.1016/j.jaad.2021.10.063
State	Published - May 2022
Externally published	Yes

Keywords

calciphylaxis
calcium
clinical trials
ESRD
palliative care
sodium thiosulfate

Access to Document

10.1016/j.jaad.2021.10.063

Cite this

@article{d349da1ab3a14788a6d94707cac21f59,

title = "Calciphylaxis: Treatment and outlook—CME part II",

abstract = "Calciphylaxis is a rare and devastating condition with important systemic ramifications. This second-part of our CME aims to educate the practicing dermatologist on the current standard of care once a diagnosis of calciphylaxis is confirmed or highly suspected. The key pathologic findings, as well as the role and limitations of biopsy, are reviewed. We aim to guide readers through the complex hospitalization and posthospitalization management of these medically vulnerable patients. Collaboration with other specialists will be discussed. Experimental and developing treatments are discussed, and the outlook of the condition is reported.",

keywords = "calciphylaxis, calcium, clinical trials, ESRD, palliative care, sodium thiosulfate",

author = "Jonathan Rick and Renajd Rrapi and Sidharth Chand and Shinohara, {Michi M.} and Lindsay Strowd and Pasieka, {Helena B.} and Robert Micheletti and Daniela Kroshinsky and Ortega-Loayza, {Alex G.}",

note = "Publisher Copyright: {\textcopyright} 2022 American Academy of Dermatology, Inc.",

year = "2022",

month = may,

doi = "10.1016/j.jaad.2021.10.063",

language = "English",

volume = "86",

pages = "985--992",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

number = "5",

}

TY - JOUR

T1 - Calciphylaxis

T2 - Treatment and outlook—CME part II

AU - Rick, Jonathan

AU - Rrapi, Renajd

AU - Chand, Sidharth

AU - Shinohara, Michi M.

AU - Strowd, Lindsay

AU - Pasieka, Helena B.

AU - Micheletti, Robert

AU - Kroshinsky, Daniela

AU - Ortega-Loayza, Alex G.

PY - 2022/5

Y1 - 2022/5

N2 - Calciphylaxis is a rare and devastating condition with important systemic ramifications. This second-part of our CME aims to educate the practicing dermatologist on the current standard of care once a diagnosis of calciphylaxis is confirmed or highly suspected. The key pathologic findings, as well as the role and limitations of biopsy, are reviewed. We aim to guide readers through the complex hospitalization and posthospitalization management of these medically vulnerable patients. Collaboration with other specialists will be discussed. Experimental and developing treatments are discussed, and the outlook of the condition is reported.

AB - Calciphylaxis is a rare and devastating condition with important systemic ramifications. This second-part of our CME aims to educate the practicing dermatologist on the current standard of care once a diagnosis of calciphylaxis is confirmed or highly suspected. The key pathologic findings, as well as the role and limitations of biopsy, are reviewed. We aim to guide readers through the complex hospitalization and posthospitalization management of these medically vulnerable patients. Collaboration with other specialists will be discussed. Experimental and developing treatments are discussed, and the outlook of the condition is reported.

KW - calciphylaxis

KW - calcium

KW - clinical trials

KW - ESRD

KW - palliative care

KW - sodium thiosulfate

UR - http://www.scopus.com/inward/record.url?scp=85128139705&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2021.10.063

DO - 10.1016/j.jaad.2021.10.063

M3 - Review article

C2 - 35202773

AN - SCOPUS:85128139705

SN - 0190-9622

VL - 86

SP - 985

EP - 992

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5

ER -